StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Performance
Shares of NASDAQ:PIRS opened at $13.60 on Wednesday. The firm has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. The firm has a fifty day moving average price of $15.97 and a 200 day moving average price of $14.70. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned about 1.21% of Pieris Pharmaceuticals at the end of the most recent quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Read More
- Five stocks we like better than Pieris Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- Canadian Penny Stocks: Can They Make You Rich?
- How AI Implementation Could Help MongoDB Roar Back in 2025
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
